# Beta-Blockers Linked to Higher Hospitalization Risk in Certain Heart Failure Patients

- Published: 2026-11-07 13:57 UTC
- Section: Life & Health › Medicine
- Tags: beta blockers hospitalization risk, TOPCAT trial analysis, ejection fraction threshold, cardiovascular mortality
- URL: https://realtech.media/news/rt-500aefa7894e14e44a32abf7_beta_blockers_linked/

**A retrospective analysis of clinical trial data shows beta-blocker use is associated with more hospital admissions in patients with heart failure and preserved ejection fraction.**

![Beta-Blockers Linked to Higher Hospitalization Risk in Certain Heart Failure Patients](https://realtech.media/media/2026/11/f046a86f7eaf689d.jpg)
*Yuriy Kvach, Wikimedia Commons, CC BY-SA 4.0*

Investigators analyzed data from 1761 participants enrolled in the TOPCAT randomized clinical trial across North and South America to evaluate outcomes associated with beta-blocker use, according to findings published in JAMA Network Open [1]. The cohort included patients with symptomatic heart failure and a left ventricular ejection fraction of at least 45%. Among the participants, 879 were women and 882 were men, with a mean age of 71.5 years. At baseline, 1394 patients reported taking beta-blockers, and 1567 individuals had an ejection fraction of 50% or higher.

Over the observation window, 399 participants experienced hospitalizations for heart failure, and 229 cardiovascular deaths occurred. Statistical modeling revealed that beta-blocker therapy was associated with a higher risk of heart failure hospitalization in patients whose ejection fraction was 50% or greater, showing an adjusted hazard ratio of 1.74 [1]. Conversely, for patients with an ejection fraction between 45% and 49%, the association was not statistically significant, yielding a hazard ratio of 0.68. There was a notable interaction between beta-blocker treatment and the specific ejection fraction threshold.

## Differential Outcomes by Pumping Capacity

The authors reported that beta-blocker administration showed no association with changes in cardiovascular disease mortality across the analyzed groups [1]. While heart failure with reduced ejection fraction benefits from beta-blockade, heart failure with preserved ejection fraction involves structural stiffness rather than impaired contractility. The observed elevation in admissions appeared strictly within the subgroup retaining an ejection fraction of at least 50%.

## Limitations and Observational Nature

The primary trial was designed to evaluate spironolactone rather than randomize participants to beta-blockers. Consequently, baseline characteristics between patients taking beta-blockers and non-users may have differed despite multivariable statistical adjustments. The authors noted that the observed correlation does not prove direct causation and recommended further targeted clinical trials before modifying existing treatment regimens.

## Sources

1. [JAMA Network Open](https://doi.org/10.1001/jamanetworkopen.2019.16598)
2. [knowridge.com](https://knowridge.com/2026/11/common-heart-drugs-may-not-suit-every-type-of-heart-failure)

---

Source: RealTech, realtech.media — https://realtech.media/news/rt-500aefa7894e14e44a32abf7_beta_blockers_linked/